All News

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.

Resistance training, especially when paired with aerobic activity and limited TV time, was associated with the steepest reductions in type 2 diabetes risk.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

The FDA issued a CRL for cytisinicline's NDA over manufacturing deficiencies at a third-party facility, with no efficacy or safety concerns cited.

The message rate tripled, rising by 153% from 2020 to 2025, adding clinician workload and exposing equity gaps that managed care must address.

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Texas abortion ban worsens maternal mental health; SCD trials exclude 90% of adults; nutrition, hepatitis B, and cost-control gaps persist.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.

Robert Andrews, CEO, Healthcare Transformation Alliance, provides insight on what workers' compensation tells us about managing health care costs.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

A meta-analysis evaluated the efficacy of various monoclonal antibodies in treating patients with myasthenia gravis (MG).

Spanish dermatology consensus guides alopecia areata treatment escalation, highlighting JAK inhibitors, SALT-based staging, special-population care, and essential screening requirements.

The FDA approved the first oral carbapenem, tebipenem pivoxil, for complicated UTIs, offering an alternative to intravenous therapy.

Mobile health models that include artificial intelligence and smartphone imaging can help address gaps in early detection.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Changes in PrEP for HIV expand choice and reduce risk as new research continues to look for an elusive cure.

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

Peter Hotez, MD, discusses which patients may benefit most from newly approved oral COVID-19 postexposure prophylaxis.

Patients with narcolepsy type 1 reported high disease burden, including chronic symptoms like hallucinations, sleep paralysis, and difficulty concentrating.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.